Stock HALO HALOZYME THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Halozyme Therapeutics, Inc.

Equities

HALO

US40637H1095

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-04-26 EDT 		5-day change 1st Jan Change
38.57 USD +0.29% Intraday chart for Halozyme Therapeutics, Inc. -0.18% +4.36%
04-25 Halozyme Therapeutics, Inc. Announces the Election of Mahesh Krishnan, M.D. to its Board of Directors CI
04-18 Halozyme Therapeutics Insider Sold Shares Worth $768,390, According to a Recent SEC Filing MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Halozyme Therapeutics, Inc. Announces the Election of Mahesh Krishnan, M.D. to its Board of Directors
Halozyme Therapeutics Insider Sold Shares Worth $768,390, According to a Recent SEC Filing
Halozyme Therapeutics Insider Sold Shares Worth $839,100, According to a Recent SEC Filing
Halozyme Therapeutics Q4 Adjusted Earnings, Revenue Rise; Reiterates 2024 Guidance
Halozyme Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
Halozyme Therapeutics, Inc. announces an Equity Buyback for $750 million worth of its shares.
Halozyme Therapeutics, Inc. Provides Earnings Guidance for the Year 2024
Halozyme Therapeutics, Inc. authorizes a Buyback Plan.
Halozyme Announces Takeda Receives European Commission Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy
Halozyme Therapeutics Insider Sold Shares Worth $720,000, According to a Recent SEC Filing
Halozyme Therapeutics Says Argenx Gets Japan's Approval for Vyvdura to Treat Certain Generalized Myasthenia Gravis Patients
Halozyme Announces Argenx Receives Approval in Japan for Vyvdura®? Co-Formulated with Enhanze®? for Generalized Myasthenia Gravis
Halozyme Therapeutics, Inc. Provides Earnings Guidance for the Twelve Months Ended December 31, 2023
Halozyme Therapeutics Says Roche Gets European Commission's Approval for Tecentriq SC
Takeda Pharmaceutical Says US FDA Approves Hyqvia as Neuromuscular Disorder Maintenance Therapy
Halozyme Announces Takeda Receives FDA Approval for Hyqvia® Co-Formulated with Enhanze® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy
Halozyme Announces Roche Receives European Commission Approval of Tecentriq®? SC with ENHANZE®? Representing the EU's First Subcutaneous PD(L)1 Cancer Immunotherapy for Multiple Cancer Types
Halozyme Therapeutics Insider Sold Shares Worth $800,262, According to a Recent SEC Filing
Teva Pharmaceutical Unit Secures US Approval for Generic Version of Forteo
Halozyme Therapeutics Insider Sold Shares Worth $788,670, According to a Recent SEC Filing
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. HALO Stock
  4. News Halozyme Therapeutics, Inc.
  5. Other languages